Evidence map›Paper›PMID 34013493›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2021

Saving time in the radiotherapy procedures for COVID-19 pneumonia treatment. A single-institution experience.

M Bonet, S Vázquez, E García, M Visus, D Jové, O Ripol, C Solé, L Gutiérrez, J L Morales-Rull, Á Montero and 3 more

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. COVID-19 and low-dose radiation therapy.Radiation medicine and protection · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

M BonetRadiation Oncology Department, Hospital Universitari Arnau de Vilanova, Av. Alcalde Rovira Roure, 80, 25198, Lleida, Spain. mabonet.lleida.ics@gencat.cat.ORCID http://orcid.org/0000-0002-6417-0514
S VázquezRadiation Oncology Department, Hospital Universitari Arnau de Vilanova, Av. Alcalde Rovira Roure, 80, 25198, Lleida, Spain.
E GarcíaRadiation Oncology Department, Hospital Universitari Arnau de Vilanova, Av. Alcalde Rovira Roure, 80, 25198, Lleida, Spain.
M VisusRadiation Physics and Radioprotection Department, Hospital Universitari Arnau de Vilanova, Lleida, Spain.
D JovéRadiation Physics and Radioprotection Department, Hospital Universitari Arnau de Vilanova, Lleida, Spain.
O RipolRadiation Physics and Radioprotection Department, Hospital Universitari Arnau de Vilanova, Lleida, Spain.
C SoléInternal Medicine Department, Hospital Universitari Arnau de Vilanova, Lleida, Spain.
L GutiérrezInternal Medicine Department, Hospital Universitari Arnau de Vilanova, Lleida, Spain.
J L Morales-RullIRBLleida (Institut de Recerca Biomèdica de Lleida. Fundació Doctor Pifarré), Lleida, Spain.
Á MonteroRadiation Oncology Department, Hospital Universitario HM Sanchinarro, Madrid, Spain.
M AlgaraRadiation Oncology Department, Parc de Salut Mar, Universitat Autònoma de Barcelona, Barcelona, Spain.
M ArenasRadiation Oncology Department, Hospital Universitari Sant Joan de Reus, Universitat Rovira I VIrgili, Reus, Spain.
M MiraRadiation Oncology Department, Hospital Universitari Arnau de Vilanova, Av. Alcalde Rovira Roure, 80, 25198, Lleida, Spain.
Hospital Universitari Arnau de Vilanova · ESHospital Universitario HM Sanchinarro · ESHospital Universitari Sant Joan de Reus · ESUniversitat Autònoma de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe use of low dose radiotherapy (LD-RT) for the treatment of COVID-19 pneumonia is supported by biological rationale for its immunomodulatory effect. Some institutions have started to treat these patients showing encouraging results. To shorten procedure times is crucial for the comfort of symptomatic patients receiving respiratory support and to optimize institutional facilities. PATIENTS AND

methodsAt our institution, LD-RT is offered to hospitalized patients with COVID-19 pneumonia and signs of early cytokine-released syndrome on behalf of a multicenter study. We designed a coordinated process flow starting from the patient transfer to the simulation CT-scan (first-step), to the end of the LD-RT treatment (last step). The times spent on each step of the process flow were evaluated.

resultsMean age of treated patients was 83 (72-91) years-old. The timing parameters of the first 10 consecutive patients were analyzed. Except for the first (dummy run), patients were managed from the first to the last step in a median of 38 min (25-58, SD 10.67). The most time-consuming sub-process was the contouring of the treatment volumes and dosimetry.

conclusionsLD-RT is not only an encouraging option for COVID-19 pneumonia patients, but a convenient and feasible procedure if performed in a coordinated way by reducing procedure times.

Indexed as

SARS-CoV-2AgedAged, 80 and overCOVID-19HumansTime FactorsCOVID-19Low-dose radiotherapyPneumoniaProcedure timesWorkflow

Identifiers

PMID34013493
PMCPMC8133050
OpenAlexW3163836404

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.